B-Cancer	0	6	Tumour	Tumour	NN	B-NP
O	6	7	-	-	HYPH	I-NP
O	7	15	specific	specific	JJ	I-NP
O	16	28	distribution	distribution	NN	I-NP
O	29	31	of	of	IN	B-PP
O	32	37	BRCA1	BRCA1	NN	B-NP
O	38	46	promoter	promoter	NN	I-NP
O	47	53	region	region	NN	I-NP
O	54	65	methylation	methylation	NN	I-NP
O	66	74	supports	support	VBZ	B-VP
O	75	76	a	a	DT	B-NP
O	77	89	pathogenetic	pathogenetic	JJ	I-NP
O	90	94	role	role	NN	I-NP
O	95	97	in	in	IN	B-PP
B-Cancer	98	104	breast	breast	NN	B-NP
O	105	108	and	and	CC	O
B-Cancer	109	116	ovarian	ovarian	JJ	B-NP
I-Cancer	117	123	cancer	cancer	NN	I-NP
O	123	124	.	.	.	O

O	126	129	The	The	DT	B-NP
O	130	134	role	role	NN	I-NP
O	135	137	of	of	IN	B-PP
O	138	143	BRCA1	BRCA1	NN	B-NP
O	144	146	in	in	IN	B-PP
O	147	155	sporadic	sporadic	JJ	B-NP
B-Cancer	156	162	breast	breast	NN	I-NP
O	163	166	and	and	CC	O
B-Cancer	167	174	ovarian	ovarian	JJ	B-NP
I-Cancer	175	182	cancers	cancer	NNS	I-NP
O	183	190	remains	remain	VBZ	B-VP
O	191	198	elusive	elusive	JJ	B-ADJP
O	198	199	.	.	.	O

O	200	206	Direct	Direct	JJ	B-NP
O	207	218	involvement	involvement	NN	I-NP
O	219	221	of	of	IN	B-PP
O	222	227	BRCA1	BRCA1	NN	B-NP
O	228	230	in	in	IN	B-PP
O	231	234	the	the	DT	B-NP
O	235	246	development	development	NN	I-NP
O	247	249	of	of	IN	B-PP
B-Cancer	250	256	breast	breast	NN	B-NP
O	257	260	and	and	CC	O
B-Cancer	261	268	ovarian	ovarian	JJ	B-NP
I-Cancer	269	275	cancer	cancer	NN	I-NP
O	276	278	is	be	VBZ	B-VP
O	279	288	suggested	suggest	VBN	I-VP
O	289	291	by	by	IN	B-PP
O	292	295	the	the	DT	B-NP
O	296	303	finding	finding	NN	I-NP
O	304	308	that	that	IN	B-SBAR
O	309	312	the	the	DT	B-NP
O	313	318	BRCA1	BRCA1	NN	I-NP
O	319	327	promoter	promoter	NN	I-NP
O	328	334	region	region	NN	I-NP
O	335	338	CpG	CpG	NN	I-NP
O	339	345	island	island	NN	I-NP
O	346	348	is	be	VBZ	B-VP
O	349	359	methylated	methylate	VBN	I-VP
O	360	362	in	in	IN	B-PP
O	363	364	a	a	DT	B-NP
O	365	375	proportion	proportion	NN	I-NP
O	376	378	of	of	IN	B-PP
B-Cancer	379	385	breast	breast	NN	B-NP
O	386	389	and	and	CC	O
B-Cancer	390	397	ovarian	ovarian	JJ	B-NP
I-Cancer	398	405	cancers	cancer	NNS	I-NP
O	405	406	.	.	.	O

O	407	410	The	The	DT	B-NP
O	411	414	aim	aim	NN	I-NP
O	415	417	of	of	IN	B-PP
O	418	422	this	this	DT	B-NP
O	423	428	study	study	NN	I-NP
O	429	432	was	be	VBD	B-VP
O	433	435	to	to	TO	B-VP
O	436	443	compare	compare	VB	I-VP
O	444	447	the	the	DT	B-NP
O	448	457	incidence	incidence	NN	I-NP
O	458	460	of	of	IN	B-PP
O	461	466	BRCA1	BRCA1	NN	B-NP
O	467	475	promoter	promoter	NN	I-NP
O	476	482	region	region	NN	I-NP
O	483	494	methylation	methylation	NN	I-NP
O	495	497	in	in	IN	B-PP
B-Cancer	498	505	tumours	tumour	NNS	B-NP
O	506	508	in	in	IN	B-PP
O	509	514	which	which	WDT	B-NP
O	515	519	loss	loss	NN	B-NP
O	520	522	of	of	IN	B-PP
O	523	528	BRCA1	BRCA1	NN	B-NP
O	529	532	has	have	VBZ	B-VP
O	533	537	been	be	VBN	I-VP
O	538	543	shown	show	VBN	I-VP
O	544	546	to	to	TO	I-VP
O	547	551	play	play	VB	I-VP
O	552	553	a	a	DT	B-NP
O	554	558	role	role	NN	I-NP
O	559	561	in	in	IN	B-PP
O	562	574	pathogenesis	pathogenesis	NN	B-NP
O	575	576	(	(	(	O
B-Cancer	576	582	breast	breast	NN	B-NP
O	583	586	and	and	CC	O
B-Cancer	587	594	ovarian	ovarian	JJ	B-NP
I-Cancer	595	605	carcinomas	carcinoma	NNS	I-NP
O	605	606	)	)	)	O
O	607	611	with	with	IN	B-PP
O	612	615	the	the	DT	B-NP
O	616	625	incidence	incidence	NN	I-NP
O	626	628	in	in	IN	B-PP
B-Cancer	629	636	tumours	tumour	NNS	B-NP
O	637	639	in	in	IN	B-PP
O	640	645	which	which	WDT	B-NP
O	646	651	BRCA1	BRCA1	NN	B-NP
O	652	654	is	be	VBZ	B-VP
O	655	663	unlikely	unlikely	JJ	B-ADJP
O	664	666	to	to	TO	B-VP
O	667	671	play	play	VB	I-VP
O	672	673	a	a	DT	B-NP
O	674	678	role	role	NN	I-NP
O	679	681	in	in	IN	B-PP
O	682	694	pathogenesis	pathogenesis	NN	B-NP
O	694	695	.	.	.	O

O	696	704	Promoter	Promoter	NN	B-NP
O	705	711	region	region	NN	I-NP
O	712	728	hypermethylation	hypermethylation	NN	I-NP
O	729	732	was	be	VBD	B-VP
O	733	746	significantly	significantly	RB	B-ADJP
O	747	751	more	more	RBR	I-ADJP
O	752	758	common	common	JJ	I-ADJP
O	759	760	(	(	(	O
O	760	761	P	P	NN	B-NP
O	762	763	<	<	SYM	B-ADJP
O	764	765	0	0	CD	B-NP
O	765	766	.	.	.	I-NP
O	766	769	008	008	CD	I-NP
O	769	770	)	)	)	O
O	771	773	in	in	IN	B-PP
B-Cancer	774	780	breast	breast	NN	B-NP
O	781	784	and	and	CC	O
B-Cancer	785	792	ovarian	ovarian	JJ	B-NP
I-Cancer	793	799	cancer	cancer	NN	I-NP
O	800	801	(	(	(	O
O	801	802	6	6	CD	B-NP
O	802	803	/	/	SYM	I-NP
O	803	805	38	38	CD	I-NP
B-Cancer	806	813	tumours	tumour	NNS	I-NP
O	814	824	methylated	methylate	VBN	B-VP
O	824	825	)	)	)	O
O	826	830	than	than	IN	B-PP
O	831	833	in	in	IN	B-PP
B-Cancer	834	839	colon	colon	NN	B-NP
I-Cancer	840	846	cancer	cancer	NN	I-NP
O	847	848	(	(	(	O
O	848	849	0	0	CD	B-NP
O	849	850	/	/	SYM	O
O	850	852	35	35	CD	B-NP
B-Cancer	853	860	tumours	tumour	NNS	I-NP
O	861	871	methylated	methylate	VBN	B-VP
O	871	872	)	)	)	O
O	873	875	or	or	CC	O
O	876	878	in	in	IN	B-PP
B-Cancer	879	889	leukaemias	leukaemia	NNS	B-NP
O	890	891	(	(	(	O
O	891	892	0	0	CD	B-NP
O	892	893	/	/	SYM	I-NP
O	893	895	19	19	CD	I-NP
B-Cancer	896	903	samples	sample	NNS	I-NP
O	904	914	methylated	methylate	VBN	B-VP
O	914	915	)	)	)	O
O	915	916	.	.	.	O

O	917	920	The	The	DT	B-NP
O	921	932	restriction	restriction	NN	I-NP
O	933	935	of	of	IN	B-PP
O	936	941	BRCA1	BRCA1	NN	B-NP
O	942	950	promoter	promoter	NN	I-NP
O	951	957	region	region	NN	I-NP
O	958	974	hypermethylation	hypermethylation	NN	I-NP
O	975	977	to	to	TO	B-PP
B-Cancer	978	984	breast	breast	NN	B-NP
O	985	988	and	and	CC	O
B-Cancer	989	996	ovarian	ovarian	JJ	B-NP
I-Cancer	997	1003	cancer	cancer	NN	I-NP
O	1004	1006	is	be	VBZ	B-VP
O	1007	1017	consistent	consistent	JJ	B-ADJP
O	1018	1022	with	with	IN	B-PP
O	1023	1024	a	a	DT	B-NP
O	1025	1037	pathogenetic	pathogenetic	JJ	I-NP
O	1038	1042	role	role	NN	I-NP
O	1043	1045	of	of	IN	B-PP
O	1046	1051	BRCA1	BRCA1	NN	B-NP
O	1052	1060	promoter	promoter	NN	I-NP
O	1061	1072	methylation	methylation	NN	I-NP
O	1073	1075	in	in	IN	B-PP
O	1076	1081	these	these	DT	B-NP
B-Cancer	1082	1089	tumours	tumour	NNS	I-NP
O	1089	1090	.	.	.	O

O	1091	1093	We	We	PRP	B-NP
O	1094	1101	suggest	suggest	VBP	B-VP
O	1102	1106	that	that	IN	B-SBAR
O	1107	1110	the	the	DT	B-NP
O	1111	1117	rarity	rarity	NN	I-NP
O	1118	1120	of	of	IN	B-PP
O	1121	1129	observed	observe	VBN	B-NP
O	1130	1135	BRCA1	BRCA1	NN	I-NP
O	1136	1145	mutations	mutation	NNS	I-NP
O	1146	1148	in	in	IN	B-PP
O	1149	1157	sporadic	sporadic	JJ	B-NP
B-Cancer	1158	1164	breast	breast	NN	I-NP
O	1165	1168	and	and	CC	O
B-Cancer	1169	1176	ovarian	ovarian	JJ	B-NP
I-Cancer	1177	1183	cancer	cancer	NN	I-NP
O	1184	1186	is	be	VBZ	B-VP
O	1187	1190	due	due	IN	B-PP
O	1191	1193	to	to	TO	B-PP
O	1194	1197	the	the	DT	B-NP
O	1198	1205	greater	great	JJR	I-NP
O	1206	1216	likelihood	likelihood	NN	I-NP
O	1217	1219	of	of	IN	B-PP
O	1220	1225	BRCA1	BRCA1	NN	B-NP
O	1226	1238	inactivation	inactivation	NN	I-NP
O	1239	1241	by	by	IN	B-PP
O	1242	1245	non	non	AFX	B-NP
O	1245	1246	-	-	HYPH	I-NP
O	1246	1256	mutational	mutational	JJ	I-NP
O	1257	1267	mechanisms	mechanism	NNS	I-NP
O	1268	1272	such	such	JJ	B-PP
O	1273	1275	as	as	IN	I-PP
O	1276	1287	methylation	methylation	NN	B-NP
O	1287	1288	.	.	.	O

